Publikationen in Zusammenarbeit mit Forschern von University of California, San Francisco (7)

2023

  1. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2021

  1. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

    Journal of Thoracic Oncology

2020

  1. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the KEYNOTE-010 study

    Journal of Clinical Oncology, Vol. 38, Núm. 14, pp. 1580-1591

  2. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895

2019

  1. TGFb blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies

    Molecular Cancer Therapeutics, Vol. 18, Núm. 3, pp. 621-631

2014

  1. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma

    International Journal of Radiation Oncology Biology Physics, Vol. 88, Núm. 3, pp. 618-623

2011

  1. p16 INK4a expression and breast cancer risk in women with atypical hyperplasia

    Cancer Prevention Research, Vol. 4, Núm. 12, pp. 1953-1960